New drugs could prevent migraine attacks from occurring
Washington: Researchers have developed drugs that are aimed at preventing migraine attacks from occurring, rather than stopping the attacks once they have started.
These studies are the first to test monoclonal antibodies for the prevention of migraine, and both are directed against a relatively new target in migraine prevention, the calcitonin gene-related peptide, or CGRP.
Both are phase II studies, meaning larger studies are needed to confirm the results.
One study involved 163 people who had migraine from five to 14 days per month. They received either a placebo or a single IV dose of a drug called ALD403 and then were followed for 24 weeks. Those who received the drug had an average of 5.6 fewer migraine days per month, a 66-percent decrease, compared to 4.6 fewer days per month for those who received a placebo, or a 52-percent decrease. Sixteen percent of those who received the drug had no migraine days at 12 weeks, while none of those who received the placebo were free from migraine at that point.
In the other study, 217 people who had migraine four to 14 days per month received biweekly subcutaneous injections of either a placebo or a drug called LY2951742 for 12 weeks.
Those who received the drug had an average of 4.2 fewer migraine days per month at 12 weeks, or a 63-percent decrease, while those who received placebo had 3 fewer migraine days per month, or a 42-percent decrease.
More from India
More from World
More from Sports
More from Entertaiment
- SC intervenes into Khap panchayat's rape order of two UP sisters, seeks report from Akhilesh govt
- Furkan, not Tiger Memon, arrested in Pakistan
- Sheena Bora murder case: Peter Mukerjea's statement recorded, police search his Worli residence
- Sonakshi Sinha silences Twitter troll for calling her ugly and it's epic!
- Is it Hardik Patel in this viral MMS Sex Video?